Beckman Coulter, IncellDx enter partnership to further HPV research with flow cytometry
A new distribution agreement will focus on work using flow cytometry to quantify human papilloma virus (HPV) and cancer.
Beckman Coulter Life Sciences (Indianapolis, IN) and IncellDx (Menlo Park, CA) have signed a distribution agreement that focuses exclusively on clinical researchers in China, Hong Kong, and Taiwan working on the human papilloma virus (HPV) and cancer. The commercial partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification.
IncellDx's next generation (3Dx) investigational molecular assay used to quantify HPV E6, E7 mRNA in single cells has been specially optimized to run on Beckman Coulter's CytoFLEX flow cytometry system. The high-throughput system instrument has the precision to integrate E6, E7 mRNA overexpression with the measurement of cell cycle and cell proliferation.
|Beckman Coulter's CytoFLEX flow cytometer will facilitate HPV research in China, Hong Kong, and Taiwan. (Image credit: PRNewsFoto/Beckman Coulter Life Sciences)|
The hallmark of cancer research, comments Bruce Patterson, MD, CEO of IncellDx, is the quantification of oncogenes E6 and E7 in cells from the cervix, anus, or head and neck. "However, as cytology samples contain a heterogeneous mixture of normal and abnormal cells, it is critical that we are able to carry out quantification at the single-cell level," he adds.
For more information, please visit www.beckmancoulter.com and http://incelldx.com.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn